ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

WSJ BLOG/Health: A.M. Vitals: Study Shows Cancer Risk for Children Getting CT Scans

(This story has been posted on The Wall Street Journal Online's Health Blog at By Mark Long Here's what's making health news this morning: Children's CT Scans Pose Cancer Risk (WSJ): Getting two to three computed tomography head exams makes children and adolescents three times as likely to develop brain cancer--though the absolute risk is small--a study of 176,587 people published in The Lancet showed. DNA Blueprint for Fetuses Built Using Tests of Parents (New York Times): Scientists reported in a paper in Science Translational Medicine that they used new, high-speed sequencing and computational tools to deduce the DNA sequence of the fetus using a blood sample from the pregnant woman and saliva from the father. New Cancer-Gene Test Seeks to Match Drugs to Patients (WSJ): Foundation Medicine disclosed that Novartis will use its new test to genetically analyze tumors in most patients in early stage clinical trials of the Swiss drug maker's experimental treatments. Novartis Unit Recalling Birth Control Pills (WSJ): The FDA said the unit, Sandoz, is recalling 10 lots of the Introvale pills sold in the U.S. because of a packing error. Vaccines for U.S. Children May Not Be Properly Stored--Study (Reuters): A report from the Office of the Inspector General in the Department of Health and Human Services found free vaccines meant for kids in a federal program may have been stored at the wrong temperature. FDA Approves Glaxo, XenoPort Drug Horizant for Shingles-Related Disease (Dow Jones Newswires): Approval of the drug to manage postherpetic neuralgia, which affects about 100,000 Americans, follows three clinical studies involving 574 adults. First Tuberculosis Drug in 40 Years Has Otsuka Cautious (Bloomberg News): A study published in the New England Journal of Medicine shows the Japanese company's delamanid helped fight TB strains not halted by other treatments. Otsuka plans to restrict access to avoid resistance to the drug building up. -For continuously updated news from The Wall Street Journal, see at

Stock News for Novartis (NVS)
11/23/201509:20:02The FDA Approves Exelixis, Inc's New Cancer Drug
11/23/201508:46:033 Dividend Stocks You Don't Have to Babysit
11/20/201517:35:00Novartis Finalizes Settlement With Justice Department
11/20/201508:41:03How 1 Specialty-Drug Maker Hopes to Win Back Investor Trust
11/19/201509:16:045 Things GlaxoSmithKline PLC Wants You to Know
11/17/201511:40:56Why Ophthotech Corporation's Shares Soared in October
11/07/201513:40:09Momenta Slowed (Temporarily)
11/06/201512:16:03Why XOMA Shares Are Crashing
11/04/201510:20:02Is This Drug Going to Be a Big Threat to Biogen and Novartis...
11/01/201511:23:035 Healthcare Trends to Invest in for the Next 20 Years
10/31/201509:21:03Generic Copaxone Isn't Derailing Teva Pharmaceuticals...Yet
10/29/201516:07:02GlaxoSmithKline's Diverging Q3 Results Imply a Long Road to Recovery
10/28/201509:20:00GlaxoSmithKline Sees Higher Sales
10/28/201509:03:00GlaxoSmithKline Sees Higher Sales in Third Quarter But Lower...
10/27/201511:15:00Novartis Profit Hurt by U.S. Settlement -- 4th Update
10/27/201507:49:00Novartis Profit Hurt by U.S. Settlement-- Third Update
10/27/201505:50:00Global Stocks Fall Ahead of Fed Meeting
10/27/201505:05:00Novartis Profit Hurt by U.S. Settlement -- 2nd Update
10/27/201504:57:00Novartis Profit Hurt by U.S. Settlement -- Update
10/27/201504:40:00Novartis Profit Hurt by U.S. Settlement

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations